



Announcement

08.11.2011

NeuroSearch publishes the MermaiHD study in The Lancet Neurology

The MermaiHD fase III study of Huntexil[®] (pridopidine) for the treatment of the motor symptoms associated with Huntington's disease has been described in a scientific article accepted by the well-reputed journal The Lancet Neurology. The article will be published electronically today and later on in a printed version entitled:

"Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial"

The Lancet Neurology has found the article worthy of a separate press release in which Dr Andrew Feigin, The Feinstein Institute for Medical Research, New York, USA, is quoted as follows:

"A well tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder... Analysis of individual items within the UHDRS-TMS in the MermaiHD study also suggests that pridopidine might benefit features of HD for which there are currently no treatments (eye movements, hand coordination, dystonia, and gait or balance problems)."

Please find a link to the article [here](#), and a reprint of the article may be requested via investor@neurosearch.com

Patrik Dahlen, CEO of NeuroSearch, commented:

"We are very pleased with the academic recognition of the results obtained in MermaiHD and now look even more forward to the initiation of Prime-HD being the next Phase III study to bring us an important step forward in the process of bringing Huntexil[®] to the market."

Patrik Dahlen
CEO

Contact person

Mads P.G. Korsgaard, PhD, Manager Investor Relations & Corporate Communications, telephone: +45 4460 8309 or +45 4018 4997

About NeuroSearch

NeuroSearch is a European-based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S (NEUR) and specialising in central nervous system (CNS) disorders. The vision is to develop NeuroSearch into a profitable specialty pharmaceutical company. The strategy is primarily to complete the development and subsequently to market Huntexil[®] (pridopidine), a unique drug in clinical Phase III for the treatment of the motor symptoms of Huntington's disease.

NeuroSearch also has a portfolio of other assets for outlicensing or divestment. This includes tesofensine which has shown outstanding efficacy in the treatment of obesity, the Integrative Screening Process (ISP), which is a proprietary systems biology approach, as well as a broad range of ion channel technologies and patented compounds identified as ion channel modulators.

